Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-003743-29 | EudraCT Number | ||
| 66525433IBD1001 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Sponsor Decision.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2) multiple, ascending oral doses of JNJ 66525433, administered to healthy participants once daily over 14 consecutive days (Part 2), and 3) multiple oral doses of JNJ 66525433, administered once daily over 14 consecutive and once daily over 42 consecutive days in participants with ulcerative colitis (UC) (Part 3).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JNJ-66525433 | Experimental | Participants will receive JNJ-66525433 in increasing dose level 1 to dose level 4 in Parts 1, 2, and dose level 3 in part 3. |
|
| Placebo | Placebo Comparator | Participants will receive matching placebo in Parts 1, 2 and 3. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JNJ-66525433 | Drug | Participants will receive JNJ-66525433 oral capsules. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1, 2 and 3: Number of Participants with Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability | An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Any AE occurring at or after the initial administration of study intervention through the day of last dose plus 30 days will be considered as TEAE. | Up to 224 Days |
| Part 1, 2 and 3: Number of Participants with Vital Sign Abnormalities | Number of participants with vital sign abnormalities (temperature), pulse/heart rate, respiratory rate and blood pressure) will be reported. | Up to 224 Days |
| Part 1, 2 and 3: Number of Participants with Physical Examination Abnormalities | Number of participants with physical examination abnormalities will be reported. | Up to 224 Days |
| Part 1, 2 and 3: Number of Participants with Hematology Laboratory Abnormalities | Number of participants with hematology laboratory abnormalities will be reported. | Up to 224 Days |
| Part 1, 2 and 3: Number of Participants with Chemistry Laboratory Abnormalities | Number of participants with chemistry laboratory abnormalities will be reported. | Up to 224 Days |
| Part 1, 2 and 3: Number of Participants with Urinalysis Laboratory Abnormalities | Number of participants with abnormalities in urinalysis will be reported. | Up to 224 Days |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1, 2 and 3: Plasma Concentrations of JNJ-66525433 | Plasma concentrations of JNJ-66525433 will be reported. | Up to 224 Days |
| Part 1: Plasma Concentrations of JNJ-66525433 After Fasted or Fed Dosing |
Not provided
Inclusion Criteria:
For Part 1 and Part 2, healthy volunteers
For Part 3, participants with ulcerative colitis (UC)
Exclusion Criteria:
For Part 1 and Part 2, healthy volunteers
For Part 3, participants with UC
COVID-related
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Charite Research Organisation GmbH | Berlin | 10117 | Germany |
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D003092 | Colitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Participants will receive matching placebo oral capsules. |
|
| Part 2 and 3: Number of Participants with Abnormalities in High Sensitivity C- Reactive Protein (hs-CRP) | Number of participants with abnormalities in hs-CRP will be reported using a validated, high sensitivity CRP assay. | Up to 224 Days |
| Part 2 and 3: Number of Participants with Abnormalities in Fecal Calprotectin | Assays for fecal calprotectin will be performed using a validated method. | Up to 224 Days |
| Part 2 and 3: Incidence of Enteric Pathogens in Stool Samples | Stool culture and Clostridium difficile toxin assay will be used for enteric pathogen assessment. | Up to 224 Days |
| Part 1, 2 and 3: Number of Participants with Electrocardiogram (ECG) Abnormalities | Number of participants with ECG abnormalities will be reported. | Up to 224 Days |
Plasma concentrations of JNJ-66525433 after fasted or fed dosing will be reported.
| Up to Day 14 |
| Part 3: Mayo Score | Mayo scoring system is used for assessment of ulcerative colitis activity. The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings) each ranges from 0 to 3. The Mayo score is calculated as the sum of these 4 subscores and can range between 0 and 12, where higher score indicates severe disease. | Up to Day 84 |
| Part 3: Partial Mayo Score | Partial Mayo score is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, and physician's global assessment) and ranges from 0 to 9 points. Higher score indicates severe disease. | Up to Day 70 |
| Part 3: Endoscopic Subscore | Endoscopy sub-score ranges from 0 to 3 where; 0 = normal or inactive disease; 1 = mild disease (erythema, decreased vascular pattern, mild friability); 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions); 3 = severe disease (spontaneous bleeding, ulceration). | Up to Day 84 |
| Part 3: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score | IBDQ18 is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes. | Days 1, 7, 14, 28, 43, 70 and 84 |
| Part 2 and 3: Target Engagement of Messenger Ribonucleic Acid (mRNA) Levels | Levels of mRNA knockdown will be reported to assess target engagement in biopsy tissue by dose level over time. | Up to 182 Days |
| Part 2 and 3: Tissue Biopsy JNJ-66525433 Concentrations | Tissue biopsy concentrations of JNJ-66525433 will be reported. | Up to 182 Days |
| Plasma Concentrations of JNJ-66525433 After Two Meal Timing Conditions | Plasma concentrations of JNJ-66525433 after two meal timing condition (fed state to modified fasted state) will be reported (if conducted). | Up to 22 Days |
| Faecal Concentrations of JNJ-66525433 After Two Meal Timing Conditions | Stool assessment will be done to characterize the presence of JNJ-66525433 after two meal timing conditions (fed state to modified fasted state) will be reported (if conducted). | Predose, up to 120 hours postdose |
| D015212 |
| Inflammatory Bowel Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |